Here are what the editors at HealthDay consider to be the most important developments in Infectious Disease for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Antibiotics, Acid Suppressants in Infancy May Up Obesity Risk
WEDNESDAY, Oct. 31, 2018 (HealthDay News) — Prescription of antibiotics and acid-suppressing medications in early childhood is associated with an increased risk for obesity, according to a study published online Oct. 30 in Gut.
AMA Announces Initiative to Reinvent Physician Training
TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.
Community Health Worker Intervention Beneficial
TUESDAY, Oct. 30, 2018 (HealthDay News) — A standardized community health worker (CHW)-delivered intervention, Individual Management for Patient-Centered Targets, improves patient-perceived quality of care and reduces hospitalizations for low-income patients with chronic diseases, according to a study published online Oct. 22 in JAMA Internal Medicine.
Health Officers Express Concerns About Vaccine Exemptions
MONDAY, Oct. 29, 2018 (HealthDay News) — After the passage of Senate Bill 277 (SB277) in California, which eliminated nonmedical vaccine exemptions for school entry, health officers and immunization staff reported concerns including an increase in medical exemptions, according to a study published online Oct. 29 in Pediatrics.
Low Levels of Flu Reported in U.S. From May to October
MONDAY, Oct. 29, 2018 (HealthDay News) — From May 20 to Oct. 13, 2018, low levels of influenza activity were reported in the United States, according to a study published online Oct. 25 in Morbidity and Mortality Weekly Report.
Many Hospitals Noncompliant With Record Request Regulations
MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.
In Complicated UTI, Cefiderocol Noninferior to Imipenem-Cilastin
MONDAY, Oct. 29, 2018 (HealthDay News) — For complicated urinary tract infections caused by multidrug-resistant Gram-negative uropathogens, the siderophore cephalosporin cefiderocol is non-inferior to imipenem-cilastatin, according to a study published online Oct. 25 in The Lancet Infectious Diseases.